Author: Ansun Biopharma, Inc.

Ansun Biopharma Announces Independent Data Monitoring Committee Recommendation Supporting Continued Phase 3 Development of DAS181 in Immunocompromised Patients with Parainfluenza Infection

June 1, 2026

Ansun Biopharma Announces Independent Data Monitoring Committee Recommendation Supporting Continued Phase 3 Development of DAS181 in Immunocompromised Patients with Parainfluenza Infection